利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.028 秒)

    Trospium containing compositions
    1.
    发明申请
    Trospium containing compositions 审中-公开
    含有Trospium的组合物

    公开(公告)号：US20070041912A1

    公开(公告)日：2007-02-22

    申请号：US10550471

    申请日：2003-09-04

    申请人： Elliot Ehrich ,  Daniel Deaver ,  Robert Clarke ,  Michael Lipp

    发明人： Elliot Ehrich ,  Daniel Deaver ,  Robert Clarke ,  Michael Lipp

    IPC分类号： A61K31/4747 ,  A61L9/04

    CPC分类号： A61K9/0078 ,  A61K9/0075 ,  A61K9/1617 ,  A61K31/40 ,  A61K31/438 ,  A61K31/46 ,  A61K45/06

    摘要： The invention relates to a method for treating a disease characterized by a constrictive airway comprising administering to a patient in need thereof via inhalation a pharmaceutical composition comprising trospium, wherein said patient achieves an effective therapy for at least 10 hours. The trospium composition is preferably a particulate formulation useful for administration via a dry powder inhaler. In a preferred embodiment, the composition further comprises a second active agent, such as a beta-2 agonist. A particularly preferred second active agent is formoterol, wherein the trospium, formoterol composition is manufactured by spray drying a mixture comprising trospium and formoterol.

    摘要翻译： 本发明涉及用于治疗特征在于缩窄性气道的疾病的方法，其包括通过吸入给予有需要的患者包含trospium的药物组合物，其中所述患者达到有效治疗至少10小时。 ium组合物优选是可用于通过干粉吸入器施用的颗粒制剂。 在优选的实施方案中，组合物还包含第二活性剂，例如β-2激动剂。 特别优选的第二活性剂是福莫特罗，其中通过将包含trospium和福莫特罗的混合物喷雾干燥来制备tro石福莫特罗组合物。

    Methods and compositions for the treatment of brain reward system disorders by combination therapy
    2.
    发明申请
    Methods and compositions for the treatment of brain reward system disorders by combination therapy 审中-公开
    通过联合治疗治疗脑回报系统疾病的方法和组合物

    公开(公告)号：US20070099947A1

    公开(公告)日：2007-05-03

    申请号：US11591842

    申请日：2006-11-02

    申请人： Reginald Dean ,  Daniel Deaver ,  Elliot Ehrich

    发明人： Reginald Dean ,  Daniel Deaver ,  Elliot Ehrich

    IPC分类号： A61K31/485 ,  A61K31/4745

    CPC分类号： A61K45/06 ,  A61K31/4745 ,  A61K31/485 ,  A61K2300/00

    摘要： The present invention is directed to a combination treatment of an opioid antagonist e.g., naltrexone and a second compound selected from the group consisting of a GABA B agonist, an NMDA antagonist, a serotonin antagonist, and a cannabinoid antagonist is the key to the successful treatment of a brain reward system disorder. A brain reward system, include but are not limited, to pathological gambling, compulsive alcohol consumption, compulsive over-eating and obesity, compulsive smoking, and drug addiction. The compounds and methods of the present invention effectively reduce the cravings, withdrawal symptoms and negative drug side effects associated with a monotherapy. As such, patient compliance is greatly increased, thereby decreasing relapse of a brain reward system disorder.

    摘要翻译： 本发明涉及阿片样物质拮抗剂的组合治疗，例如纳曲酮和选自GABA B激动剂，NMDA拮抗剂，5-羟色胺拮抗剂和大麻素拮抗剂的第二化合物是成功治疗的关键 的脑回报系统障碍。 大脑奖励制度包括但不限于病理赌博，强迫性酒精消费，强迫性过度饮食和肥胖，强迫性吸烟和吸毒成瘾。 本发明的化合物和方法有效地减少与单一疗法相关的渴望，戒断症状和药物副作用。 因此，患者顺应性大大增加，从而减少脑回报系统障碍的复发。

    Naltrexone long acting formulations and methods of use
    3.
    发明授权
    Naltrexone long acting formulations and methods of use 有权
    纳曲酮长效制剂及使用方法

    公开(公告)号：US07919499B2

    公开(公告)日：2011-04-05

    申请号：US11083167

    申请日：2005-03-17

    申请人： Elliot Ehrich

    发明人： Elliot Ehrich

    IPC分类号： A61K31/44 ,  A61K31/56 ,  A01N43/42 ,  A01N45/00 ,  A61F13/00

    CPC分类号： A61K47/34 ,  A61K9/0019 ,  A61K9/1641 ,  A61K31/485

    摘要： The inventions described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes a method for treating an individual in need of naltrexone comprising the step of parenterally administering a long acting formulation comprising naltrexone and to the use of naltrexone in the manufacture of medicaments for use in such methods.

    摘要翻译： 本文描述的发明源于在使用纳曲酮的长效制剂的临床试验期间发生的意想不到的发现。 因此，本发明包括用于治疗需要纳曲酮的个体的方法，包括以下步骤：肠胃外施用包含纳曲酮的长效制剂和使用纳曲酮制造用于此类方法的药物。

    Methods for treating alcoholism
    4.
    发明申请
    Methods for treating alcoholism 审中-公开
    酒精中毒治疗方法

    公开(公告)号：US20050245541A1

    公开(公告)日：2005-11-03

    申请号：US11082534

    申请日：2005-03-17

    申请人： Elliot Ehrich ,  Trevor Mundel

    发明人： Elliot Ehrich ,  Trevor Mundel

    IPC分类号： A61K31/445 ,  A61K31/485 ,  A61K31/495

    CPC分类号： A61K45/06 ,  A61K31/485 ,  A61K31/496 ,  A61K2300/00

    摘要： In the treatment of alcoholism, co-treatment with an active agent capable of offsetting unwanted adverse clinical manifestations to the treatment itself, for example, negative drug adverse clinical manifestations, greatly increases patient compliance. Increasing patient compliance, in turn, creates a better success rate and decreased recidivism or relapse. The current invention combines the use of an opioid antagonist with at least one dopamine D2 partial agonist for the treatment of alcoholism. Suitable dopamine D2 partial agonists are aripiprazole and (−)3-(3-hydroxyphenyl)-N-n-propylpiperidine [(−)-3PPP].

    摘要翻译： 在治疗酒精中毒方面，与能够抵消不良临床表现的活性剂与治疗本身进行共同治疗，例如负药物不利临床表现，大大提高了患者的依从性。 反过来，增加患者依从性可以创造更好的成功率，减少再次发生或复发。 本发明结合了阿片样物质拮抗剂与至少一种多巴胺D2部分激动剂在治疗酒精中毒中的用途。 合适的多巴胺D2部分激动剂是阿立哌唑和（ - ）3-（3-羟基苯基）-N-正丙基哌啶[（ - ） - 3PPP]。

    Naltrexone Long Acting Formulations and Methods of Use
    6.
    发明申请
    Naltrexone Long Acting Formulations and Methods of Use 审中-公开
    纳曲酮长效配方及使用方法

    公开(公告)号：US20110212985A1

    公开(公告)日：2011-09-01

    申请号：US13037713

    申请日：2011-03-01

    申请人： Elliot Ehrich

    发明人： Elliot Ehrich

    IPC分类号： A61K31/485 ,  A61P25/32

    CPC分类号： A61K47/34 ,  A61K9/0019 ,  A61K9/1641 ,  A61K31/485

    摘要： The inventions described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes a method for treating an individual in need of naltrexone comprising the step of parenterally administering a long acting formulation comprising naltrexone and to the use of naltrexone in the manufacture of medicaments for use in such methods.

    摘要翻译： 本文描述的发明源于在使用纳曲酮的长效制剂的临床试验期间发生的意想不到的发现。 因此，本发明包括用于治疗需要纳曲酮的个体的方法，包括以下步骤：肠胃外施用包含纳曲酮的长效制剂和使用纳曲酮制造用于此类方法的药物。

    Methods for treating alcoholism
    7.
    发明申请
    Methods for treating alcoholism 审中-公开
    酒精中毒治疗方法

    公开(公告)号：US20050245461A1

    公开(公告)日：2005-11-03

    申请号：US11082420

    申请日：2005-03-17

    申请人： Elliot Ehrich ,  Trevor Mundel

    发明人： Elliot Ehrich ,  Trevor Mundel

    IPC分类号： A61K31/198 ,  A61K31/4164 ,  A61K31/42 ,  A61K31/485 ,  A61K31/515 ,  A61K31/55 ,  A61K31/7008

    CPC分类号： A61K45/06 ,  A61K31/195 ,  A61K31/485 ,  A61K31/55 ,  A61K2300/00

    摘要： In the treatment of alcoholism, co-treatment with an active agent capable of offsetting unwanted adverse clinical manifestations to the treatment itself, for example, negative drug adverse clinical manifestations, greatly increases patient compliance. Increasing patient compliance, in turn, creates a better success rate and decreased recidivism or relapse. The current invention combines the use of an opioid antagonist with at least one anticonvulsant for the treatment of alcoholism.

    摘要翻译： 在治疗酒精中毒方面，与能够抵消不良临床表现的活性剂与治疗本身进行共同治疗，例如负药物不利临床表现，大大提高了患者的依从性。 反过来，增加患者依从性可以创造更好的成功率，减少再次发生或复发。 本发明结合阿片样物质拮抗剂与至少一种用于治疗酒精中毒的抗惊厥药的用途。

    Methods of Treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers
    9.
    发明申请
    Methods of Treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers 审中-公开
    使用组合药物治疗和可溶胀聚合物治疗酒精中毒和酒精相关疾病的方法

    公开(公告)号：US20090214650A1

    公开(公告)日：2009-08-27

    申请号：US12162801

    申请日：2007-02-01

    申请人： Elliot Ehrich

    发明人： Elliot Ehrich

    IPC分类号： A61K9/14 ,  A61K31/485 ,  A61K31/195 ,  A61P25/32

    CPC分类号： A61K45/06 ,  A61K31/195 ,  A61K31/473 ,  A61K2300/00

    摘要： The current invention provides methods of treating alcohol related disorders by providing a sustained release oral drug dosage form comprising a plurality of solid state drugs i.e., baclofen and naltrexone, dispersed in a solid state unitary matrix formed from a combination of swellable polymers. The combination of swellable polymers in a single oral drug dosage form is beneficial in terms of release rate control for combination therapies.

    摘要翻译： 本发明提供了通过提供分散在由可溶胀聚合物的组合形成的固态酉基质中的多种固态药物即巴氯芬和纳曲酮的缓释口服药物剂型来治疗酒精相关疾病的方法。 在单一口服药物剂型中的可溶胀聚合物的组合在组合疗法的释放速率控制方面是有益的。

    Methods for Administering Active Agents to CYP3A4 Sensitive Patients
    10.
    发明申请
    Methods for Administering Active Agents to CYP3A4 Sensitive Patients 审中-公开
    将活性剂用于CYP3A4敏感性患者的方法

    公开(公告)号：US20090022823A1

    公开(公告)日：2009-01-22

    申请号：US12241404

    申请日：2008-09-30

    申请人： Elliot Ehrich ,  Trevor Mundel

    发明人： Elliot Ehrich ,  Trevor Mundel

    IPC分类号： A61K31/496 ,  A61K36/752 ,  A61K31/7048 ,  A61K31/56 ,  A61K31/551 ,  A61K38/13 ,  A61P25/00

    CPC分类号： A61K31/554 ,  A61K31/704 ,  A61K31/7048

    摘要： The present invention relates, in part, to the discovery that parenterally administered extended release formulations possess an unexpected advantage in treating patients possessing active CYP 3A4. This advantage is particularly beneficial where the individual is concomitantly administering a CYP 3A4 inhibitor or is in risk of doing so.Thus, the invention relates to a method for treating individuals possessing a functional CYP3A4 gene with an active agent metabolized by CYP3A4 comprising parenterally administering the active agent in a first extended release formulation in a first administration and the formulations for use in such methods.The invention further includes a method for preventing adverse drug reactions in individuals possessing a functional CYP3A4 gene with an active agent metabolized by CYP3A4 comprising parenterally administering the active agent in a first extended release formulation in a first administration.

    摘要翻译： 本发明部分地涉及胃肠外给药的延长释放制剂在治疗患有活性CYP 3A4的患者方面具有意想不到的优势的发现。 当个体伴随地施用CYP 3A4抑制剂或者有这样做的风险时，这个优点是特别有益的。 因此，本发明涉及一种用CYP3A4代谢的活性剂治疗患有功能性CYP3A4基因的个体的方法，包括在第一次给药中在第一延长释放制剂中肠胃外施用活性剂，以及用于该方法的制剂。 本发明还包括一种用于在具有功能性CYP3A4基因的个体中预防不良药物反应的方法，所述药物CYP3A4由CYP3A4代谢的活性剂包括在第一次施用中在第一延长释放制剂中肠胃外给药所述活性剂。